Back

Proprotein convertase subtilisin/kexin type 9 (PCSK9), platelet activation and risk of cardiovascular events in atrial fibrillation

27 August 2017 (08:30 - 12:30)
Organised by:
Congress Presentation Part of: Poster session 2 - Coronary artery disease: from bench to bedside Thrombosis and coagulation ESC Premium Access ESC Congress 2017

About the speaker

Photo
Professor Pasquale Pignatelli Spinazzola

Sapienza University of Rome, Rome (Italy)

71 More presentations in this session

Presentation thumbnail
Doctor G. Chi (Boston, US)
Abstract Slides
Presentation thumbnail
Doctor B. Mahmoodi (Rotterdam, NL)
Abstract Slides
Presentation thumbnail
Professor L. Rallidis (Athens, GR)
Abstract Slides
Presentation thumbnail
Doctor J. Adjedj (Saint Laurent du Var, FR)
Abstract Slides
Presentation thumbnail
Professor K. Karamfiloff (Sofia, BG)
Abstract Slides

Access the full session

Session thumbnail
Poster session 2 - Coronary artery disease: from bench to bedside

The Event

Event poster

ESC Congress 2017

27 August 2017 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Association of circulating proprotein convertase subtilisin/kexin type 9 concentration with prothrombin time in patients with chest pain
28 August 2020
thumbnail
Congress Session
Stroke and bleeding risk in atrial fibrillation: walking the tight rope
25 August 2023
thumbnail
Congress Presentation
Alirocumab prevents atrial fibrillation in hypertension and obese mice through alleviation of PCSK9 induced atrial remodeling by regulating arachidonic acid metabolism
30 August 2025
thumbnail
Congress Presentation
The association between dyslipidaemia treatment and the risk of clinical events in edoxaban-treated patients with atrial fibrillation: insights from the 2-year follow-up of ETNA-AF-Europe
28 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources